1.
Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
by Attard, Gerhardt
The journal of clinical endocrinology and metabolism, 2012, Vol.97 (2), p.507-516
2.
3.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
by Yuen, Kobe C
Nature medicine, 2020, Vol.26 (5), p.693-698
4.
Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib
by Kodama, Kenichiro
Oncology, 2019, Vol.97 (2), p.75-81
5.
The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC?
by Simon, Yvette
Gut, 2014, Vol.63 (5), p.861-863
6.
7.
Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
by Bengtsson, Daniel
The journal of clinical endocrinology and metabolism, 2015, Vol.100 (4), p.1689-1698
8.
Neuro-oncologic Applications of Exosomes, Microvesicles, and Other Nano-Sized Extracellular Particles
by Gonda, David D
Neurosurgery, 2013, Vol.72 (4), p.501-510
9.
Predictors for Microinvasion of Small Hepatocellular Carcinoma ≤2 cm
by Yamashita, Yo-ichi
Annals of surgical oncology, 2011, Vol.19 (6), p.2027-2034
10.
Craniopharyngiomas Express Embryonic Stem Cell Markers (SOX2, OCT4, KLF4, and SOX9) as Pituitary Stem Cells but Do Not Coexpress RET/GFRA3 Receptors
by Garcia-Lavandeira, Montserrat
The journal of clinical endocrinology and metabolism, 2012, Vol.97 (1), p.E80-E87
11.
Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers
by Ikeda, Hiroko
American journal of clinical pathology, 2013, Vol.140 (3), p.329-340
12.
p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury
by Marhenke, Silke
Gut, 2014, Vol.63 (9), p.1501-1512
13.
Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation
by Johnson, Erik C B
Nature medicine, 2020, Vol.26 (5), p.769-780
14.
Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells
by Nam, Ki Taek
Gut, 2012, Vol.61 (12), p.1678-1685
15.
Biomarker Modeling of Alzheimer’s Disease
by Jack, Clifford R
Neuron (Cambridge, Mass.), 2013, Vol.80 (6), p.1347-1358
16.
Biomarker development, from bench to bedside
by Stenman, Ulf-Håkan
Critical reviews in clinical laboratory sciences, 2016, Vol.53 (2), p.69-86
17.
Circulating biomarker panels for targeted therapy in brain tumors
by Tanase, Cristiana
Future oncology (London, England), 2015, Vol.11 (3), p.511-524
18.
Exploring the link between diabetes and pancreatic cancer
by Pizzato, Margherita
Expert review of anticancer therapy, 2019, Vol.19 (8), p.681-687
19.
Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms
by Schmitt, Anja Maria
Neuroendocrinology, 2014, Vol.100 (1), p.35-44
20.
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
by Heerspink, Hiddo J. L
Diabetologia, 2019, Vol.62 (7), p.1154-1166
